Loyal Valley Capital logo

Loyal Valley Capital

Asia, Shanghai, China, Shanghai

Description

Loyal Valley Capital (LVC) is a prominent private equity firm based in Shanghai, China, established in 2015. The firm distinguishes itself through a thematic, research-driven investment approach, primarily targeting growth-stage companies within China's rapidly evolving economy. LVC focuses on identifying and backing businesses with strong fundamentals and significant growth potential across several key sectors, aiming to generate long-term value through active partnership with its portfolio companies.

LVC's investment strategy is deeply rooted in macro-level thematic research, allowing them to anticipate industry trends and identify leading players. Their core investment themes typically span high-growth sectors such as consumer goods and services, healthcare, advanced manufacturing, and technology, media, and telecom (TMT). The firm manages a substantial asset base, with its total assets under management (AUM) exceeding $3 billion across multiple USD and RMB-denominated funds, underscoring its significant presence in the Chinese private equity landscape.

The firm has demonstrated strong fundraising capabilities, successfully closing several substantial funds. In 2021, Loyal Valley Capital closed its third USD-denominated fund, Loyal Valley Capital USD Fund III, at an impressive $600 million. Concurrently, they also closed their second RMB fund, Loyal Valley Capital RMB Fund II, raising RMB 3.5 billion (approximately $540 million). These successful fundraises provide LVC with considerable capital to deploy into promising growth-stage enterprises.

LVC's disciplined approach and focus on fundamental value creation have positioned it as a key investor in China's new economy. By leveraging its deep industry insights and extensive network, the firm aims to empower innovative companies, contributing to their scaling and market leadership. Their strategic investments are designed to capitalize on China's domestic consumption upgrade, technological advancements, and industrial transformation, solidifying their reputation as a sophisticated and influential private equity player.

Investor Profile

Loyal Valley Capital has backed more than 25 startups, with 1 new investments in the last 12 months alone. The firm has led 11 rounds, about 44% of its total and boasts 23 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in China, Hong Kong, United States.
  • Strong thematic focus on Biotechnology, Health Care, Manufacturing.
  • Led 1 rounds in the past year.
  • Typical check size: $20M – $100M.

Stage Focus

  • Series B (28%)
  • Series C (24%)
  • Series A (12%)
  • Series D (12%)
  • Private Equity (8%)
  • Angel (4%)
  • Post Ipo Equity (4%)
  • Series E (4%)
  • Series Unknown (4%)

Country Focus

  • China (92%)
  • Hong Kong (4%)
  • United States (4%)

Industry Focus

  • Biotechnology
  • Health Care
  • Manufacturing
  • Life Science
  • Therapeutics
  • Pharmaceutical
  • Content
  • E-learning
  • Education
  • Children
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Loyal Valley Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 4
Tencent
Asia, Guangdong, China, Shenzhen
Co-Investments: 3
Morningside Group
North America, Massachusetts, United States, Newton Center
Co-Investments: 3
Lighthouse Capital Partners
North America, California, United States, Menlo Park
Co-Investments: 3
Temasek Holdings
Asia, Central Region, Singapore, Singapore
Co-Investments: 3
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 4
China Renaissance
Asia, Beijing, China, Beijing
Co-Investments: 2
CMC Capital Group
Asia, Shanghai, China, Shanghai
Co-Investments: 2
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 4
Boyu Capital
Asia, Beijing, China, Beijing
Co-Investments: 3

Which angels does Loyal Valley Capital often collaborate with?

WM
North America, New York, United States, New York
Shared Deals: 1
Adrian Cheng
Asia, Hong Kong
Shared Deals: 1

What are some of recent deals done by Loyal Valley Capital?

Core Medical Technology

Shenzhen, Guangdong, China

Core Medical Technology develops ventricular assist devices and equipment.

ManufacturingMedicalMedical Device
Series DApr 24, 2025
Amount Raised: $100,000,000
Jinyuansheng

Shanghai, Shanghai, China

Jinyuansheng is a supplier of new energy batteries.

Clean EnergyEnergy
Series BAug 15, 2022
Amount Raised: $147,634,163
Frontera Therapeutics

Bedford, Massachusetts, United States

Frontera Therapeutics is an AAV gene therapy company that focuses on rAAV therapies for the global market.

Biotechnology
Series BJun 24, 2022
Amount Raised: $160,000,000
Alebund Pharmaceuticals

Shanghai, Shanghai, China

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases.

BiotechnologyLife SciencePharmaceutical
Series BSep 13, 2021
Amount Raised: $54,500,000
Abogen Biosciences

Suzhou, Jiangsu, China

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.

BiotechnologyGeneticsLife Science
Series CAug 19, 2021
Amount Raised: $1,000,000,000
Jcet

Jiangyin, Jiangsu, China

JCET Group manufactures semiconductor products.

IndustrialIndustrial ManufacturingManufacturing
Post Ipo EquityMay 7, 2021
Amount Raised: $777,302,759
Arctic Vision

Shanghai, Shanghai, China

Arctic Vision is focused on the development and commercialization of innovative ophthalmology therapies.

BiotechnologyHealth CareLife Science
Series BMar 9, 2021
Amount Raised: $100,000,000
Zhishan Weixin Biotechnology

Chengdu, Sichuan, China

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases.

BiotechnologyHealth CareProduct Research
Series AFeb 9, 2021
CARsgen Therapeutics

Shanghai, Shanghai, China

CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor

Health DiagnosticsMedicalTherapeutics
Series CNov 2, 2020
Amount Raised: $186,000,000
Zhaoke Ophthalmology Pharmaceutical

Hong Kong, Hong Kong Island, Hong Kong

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

BiotechnologyPharmaceutical
Series BOct 12, 2020
Amount Raised: $145,000,000